Zobrazeno 1 - 10
of 42
pro vyhledávání: '"Nitin K Damle"'
Autor:
Sandeep Gupta, Louis J. Denis, Niranjan S. Rao, Mahesh Mistry, Jun-Hsiang Lin, Sanjeeva P. Reddy, Helen Usansky, Nitin K. Damle, David J. Zammit, Roger A. Smith
Supplementary Data and Figures S1 to S6
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0db6e8841fe5e495429a08a8f375ce73
https://doi.org/10.1158/1535-7163.22522731.v1
https://doi.org/10.1158/1535-7163.22522731.v1
Autor:
Ryan R. Walsh, Nitin K. Damle, Sanjay Mandhane, Steven P. Piccoli, Ravi S. Talluri, Damon Love, Siu-Long Yao, Vikram Ramanathan, Orest Hurko
Publikováno v:
Parkinsonism & Related Disorders. 108:105281
Autor:
Sandeep Gupta, David J. Zammit, Helen Usansky, Mahesh Mistry, L. Denis, Niranjan Rao, Jun-Hsiang Lin, Sanjeeva Reddy, Roger Astbury Smith, Nitin K Damle
Publikováno v:
Molecular cancer therapeutics. 20(8)
The 5T4 oncofetal antigen (trophoblast glycoprotein) is expressed in a wide range of malignant tumors but shows very limited expression in normal adult tissues. ASN004 is a 5T4-targeted antibody–drug conjugate (ADC) that incorporates a novel single
Autor:
Nitin K. Damle, Martin E. Dorf, Diane D. Eardley, Richard J. Hodes, Edgar G. Engleman, Pamela Hunt
Publikováno v:
Paradoxes in Immunology ISBN: 9780429286353
Paradoxes in Immunology
Paradoxes in Immunology
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f24ed414bb092ce5b5d3e9bda050d247
https://doi.org/10.1201/9780429286353-5
https://doi.org/10.1201/9780429286353-5
Publikováno v:
Cancer Chemotherapy and Pharmacology. 67:741-749
CMC-544 (inotuzumab ozogamicin) is a CD22-specific immunoconjugate of calicheamicin currently being evaluated in patients with non-Hodgkin's B-cell lymphoma (BCL). CHOP and CVP represent untargeted combination chemotherapy comprised of cyclophosphami
Autor:
Kiran Khandke, Maureen Dougher, Latha Sridharan, Erwin R. Boghaert, Inder Chaudhary, Arthur Kunz, Justin Keith Moran, Hamann Philip Ross, Nitin K. Damle, John F. DiJoseph
Publikováno v:
Cancer Chemotherapy and Pharmacology. 61:1027-1035
The present study aims to establish a method that provides fast, precise and reproducible pharmacokinetic (PK) parameters of antibody-calicheamicin conjugates. The method should discriminate between PK of the antibody moiety and PK of the conjugated
Autor:
Hamann Philip Ross, Arthur Kunz, John F. DiJoseph, Douglas Armellino, Maureen Dougher, Lyka B. Kalyandrug, Nitin K. Damle, Erwin R. Boghaert
Publikováno v:
Cancer Immunology, Immunotherapy. 56:1107-1117
Tumor-targeted delivery of a potent cytotoxic agent, calicheamicin, using its immunoconjugates is a clinically validated therapeutic strategy. Rituximab is a human CD20-specific chimeric antibody extensively used in B-NHL therapy. We investigated whe
Autor:
Barbara J. Sheppard, Evelyn Li, Jennifer Lamothe, Mary Collins, Martin Hegen, Gerald E. Hancock, Xiaochuan X. Zhou, Hak-Ling Ma, Kyri Dunussi-Joannopoulos, Hamann Philip Ross, Arthur Kunz, Nitin K. Damle
Publikováno v:
Blood. 106:2235-2243
We report the development of a mouse B cell-depleting immunoconjugate (anti-CD22 monoclonal antibody [mAb] conjugated to calicheamicin) and its in vivo use to characterize the kinetics of CD22+ B-cell depletion and reconstitution in murine primary an
Autor:
Latha Sridharan, Sue Stephens, Douglas Armellino, Nitin K. Damle, Justin Keith Moran, Hamann Philip Ross, Kiran Khandke, Chandrasekhar Udata, Andrew George Popplewell, Philip Frost, John F. DiJoseph, Maureen Dougher, Boris Gorovits, Arthur Kunz, Erwin R. Boghaert
Publikováno v:
Blood. 103:1807-1814
Antibody-targeted chemotherapy with gemtuzumab ozogamicin (CMA-676, a CD33-targeted immunoconjugate of N-acetyl-γ-calicheamicin dimethyl hydrazide [CalichDMH], a potent DNA-binding cytotoxic antitumor antibiotic) is a clinically validated therapeuti
Autor:
Venkatesan M Aranapakam, Sanjeeva Reddy, Roger A. Smith, Niranjan Rao, Amita Patnaik, Nitin K. Damle, Terry Plasse, Scott B Thompson, Drew W. Rasco, Kyriakos P. Papadopoulos, Penelope J. Bristow, Gupta Sandeep, Anthony W. Tolcher
Publikováno v:
Blood. 126:4009-4009
ASN002 is an orally bioavailable potent dual inhibitor of spleen tyrosine kinase (SYK) and Janus kinases (JAK) with low nM IC50 values in biochemical assays. It is currently under clinical evaluation in a phase I/II study for safety, tolerability, ph